Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
View/ Open
Use this link to cite
http://hdl.handle.net/2183/21219Collections
- GI-FENM - Artigos [119]
Metadata
Show full item recordTitle
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapyDate
2017-04-13Citation
Antón-Aparicio LM, Peláez Fernández I, Cassinello J. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol. 2017;19(10): 1175-1182
Abstract
[Abstract] The immune system regulates angiogenesis in cancer by way of both pro- and antiangiogenic activities. A bidirectional link between angiogenesis and the immune system has been clearly demonstrated. Most antiangiogenic molecules do not inhibit only VEGF signaling pathways but also other pathways which may affect immune system. Understanding of the role of these pathways in the regulation of immunosuppressive mechanisms by way of specific inhibitors is growing. Renal cell carcinoma (RCC) is an immunogenic tumor in which angiogenesis and immunosuppression work hand in hand, and its growth is associated with impaired antitumor immunity. Given the antitumor activity of selected TKIs in metastatic RCC (mRCC), it seems relevant to assess their effect on the immune system. The confirmation that TKIs improve cell cytokine response in mRCC provides a basis for the rational combination and sequential treatment of TKIs and immunotherapy.
Keywords
Tyrosine kinase inhibitors
Immunomodulation
Angiogenesis
Renal cell carcinoma
Immunotherapy
Immunomodulation
Angiogenesis
Renal cell carcinoma
Immunotherapy
Description
Review article
Editor version
ISSN
1699-048X